TSX VENTURE EXCHANGE: AVI
QUEBEC CITY, Oct. 10 /CNW Telbec/ - Advitech Inc. ("Advitech" or the
"Corporation") (TSX Venture Exchange: AVI) today announced that two
milk-derived protein extracts from its XP-828L technological platform have
demonstrated wound-healing properties in an in vivo study conducted by Dr.
Charles Doillon of the Oncology and Molecular Endocrinology Research Centre at
the Centre Hospitalier de l'Université Laval (CHUL). Dr. Doillon is a
recognized researcher in the field of wound healing and angiogenesis. The
study has demonstrated that both protein extracts could significantly impact
the wound-healing response, especially the formation of regenerated collagen
fibre and its remodelling in wound tissue.
"The data further confirms the bio-activity of our protein extracts and
brings new opportunities for Advitech. The results suggest that these two
products act early in the healing process and would accelerate wound-healing
without excessive long-term remodelling", stated Dr. Christina Juneau,
Vice-President, Research and Development. "Three potential fields of
application have been identified", added Dr. Juneau:
1. The management of skin ulcers, particularly pressure ulcers;
2. The improvement of scar tissue response in plastic and reconstructive
surgery and dermabrasion;
3. The acceleration of the healing process in burn wounds.
"Part of our 2007 business plan focuses on the identification of new
commercial opportunities targeting dermatological applications, with
additional revenues for the 2008 fiscal year", stated Renaud Beauchesne,
president and CEO at Advitech. "With these positive results regarding
wound-healing applications, we have achieved an additional milestone in our
plan, while developing our natural growth factor based technological platform
with respect to natural growth factors", commented Mr. Beauchesne.
According to Espicom Business Intelligence Ltd., the global wound care
market totalled $7.2 billion in 2006, with a 10% growth rate. Growth factor
based applications for wound-healing represent more than 5% of the market,
with an impressive 27% growth rate.
About Advitech Inc. www.advitech.com
Advitech is a health sciences and technology company with a mission to
discover and commercialize proprietary and evidence-based natural health
products. Effective and safe, these products play a role in the prevention of
Immune-mediated inflammatory disorders, such as psoriasis and inflammatory
bowel disease. Recently, Advitech launched Dermylex(TM) for the treatment of
About Dermylex(TM) www.dermylex.com
Dermylex(TM), developed by Advitech, is an oral natural health product
formulated to improve mild-to-moderate psoriasis symptoms. Two clinical
trials, including a 112-day, multi-center, double-blind, placebo-controlled
trial with 84 patients, clinically proved the efficacy and safety of
Dermylex(TM) for that type of psoriasis. Dermylex(TM) is currently available
in Canada and the U.S. (as BioDerm, Dermylex), and will soon be available in
France and Belgium (as Psopax).
This press release contains forward-looking statements which reflect
the Company's current expectations regarding future events. The
forward-looking statements involve risks and uncertainties. Actual
results could differ materially from those projected herein. The TSX
Venture Exchange does not accept responsibility for the adequacy or
accuracy of this release.
For further information:
For further information: Advitech Inc.: Renaud Beauchesne, MBA,
President and Chief Executive Officer, (418) 686-7498, ext. 228,
firstname.lastname@example.org, www.advitech.com; Serge Comeau, Investor's relations, (514)